Antidepressant use in pregnancy

Bibliography

• Grigoriadis S, Robinson GE. Gender issues in depression. Ann Clin Psychiatry 2007;19:247-55
   PubMedGoogle Scholar
• Bennett HA, Einarson A, Taddio A, Koren G. Prevalence of depression during pregancy: systematic review. Obstet Gynecol 2004;103:698-703
   PubMed Web of Science ®Google Scholar
• Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 1997;33(5):328-43
   PubMed Web of Science ®Google Scholar
• Freeman MP, Nolan PE Jr, Davis MF, Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008;28(6):646-53
   PubMed Web of Science ®Google Scholar
• Hendrick V, Stowe ZN, Altshuler LL, Placental passage of antidepressant medications. Am J Psychiatry 2003;160(5):993-6
   PubMed Web of Science ®Google Scholar
• Friedman JM. The principles of teratology: are they still true? Birth Defects Res A Clin Mol Teratol 2010;88(10):766-8
   PubMed Web of Science ®Google Scholar
• Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338(16):1128-37
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Koren G. Direct drug toxicity to the fetus. Medication safety in pregnancy and breastfeeding. McGraw-Hill Companies, Inc., New York; 2007. p. 85-107
   Google Scholar
• Einarson A. Studying the safety of drugs in pregnancy: and the gold standard is…. J Clin Pharmacol Pharmacoepidemiol 2008;1(1):3-8, 15
   Google Scholar
• Altshuler LL, Cohen L, Szuba MP, Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153(5):592-606
   PubMed Web of Science ®Google Scholar
• Kallen B. The safety of antidepressant drugs during pregnancy. Expert Opin Drug Saf 2007;6(4):357-70
   PubMed Web of Science ®Google Scholar
• Pastuszak A, Schick-Boschetto B, Zuber C, Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269(17):2246-8
   PubMed Web of Science ®Google Scholar
• Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol Drug Saf 2005;14(12):823-7
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Rasmussen SA, Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356(26):2684-92
   PubMed Web of Science ®Google Scholar
• Louik C, Lin AE, Werler MM, First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356(26):2675-83
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Shechtman S, Weinbaum D, Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66(5):695-705
   PubMed Web of Science ®Google Scholar
• Bakker MK, De Walle HE, Wilffert B, de Jong-Van den Berg LT. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010;19(8):808-13
   Google Scholar
• FDA.PublicHealthAdvisory: Paxil.; 2005. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051731.htm
   Google Scholar
• Wogelius P, Norgaard M, Gislum M, Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17(6):701-4
   PubMed Web of Science ®Google Scholar
• Kallen BAJ, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79(4):301-8
   PubMed Web of Science ®Google Scholar
• Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(10):1075-85
   PubMed Web of Science ®Google Scholar
• Merlob P, Birk E, Sirota L, Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009;85(10):837-41
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Vestergaard M, Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Br Med J 2009;339:b3569
   PubMed Web of Science ®Google Scholar
• Kornum JB, Nielsen RB, Pedersen L, Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010;2:29-36
   PubMedGoogle Scholar
• Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40(10):1723-33
   PubMed Web of Science ®Google Scholar
• Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88(3):159-70
   PubMed Web of Science ®Google Scholar
• Davis RL, Rubanowice D, McPhillips H, Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16(10):1086-94
   PubMed Web of Science ®Google Scholar
• Wichman CL, Moore KM, Lang TR, Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009;84(1):23-7
   PubMed Web of Science ®Google Scholar
• Vial T, Cournot MP, Bernard N, ; the FN of PC. Paroxetine and congenital malformations: a prospective comparative study. Drug Saf 2006;29:970
   Web of Science ®Google Scholar
• Einarson A, Pistelli A, DeSantis M, Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008;165(6):749-52
   PubMed Web of Science ®Google Scholar
• Hendrick V, Smith LM, Suri R, Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188(3):812-15
   PubMed Web of Science ®Google Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106(6):1289-96
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Warburton W, Misri S, Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83(1):68-76
   PubMed Web of Science ®Google Scholar
• Sivojelezova A, Shuhaiber S, Sarkissian L, Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005;193(6):2004-9
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009;54(4):242-6
   PubMed Web of Science ®Google Scholar
• Klieger-Grossmann C, Weitzner B, Panchaud A, Pregnancy outcomes following use of escitalopram: a prospective study. J Clin Pharmacol (In press)
   Google Scholar
• Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40(10):1723-33
   PubMed Web of Science ®Google Scholar
• Einarson A, Fatoye B, Sarkar M. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158(10):1728-30
   PubMed Web of Science ®Google Scholar
• Yaris F, Kadioglu M, Kesim M, Newer antidepressants in pregnancy: prospective outcome of a case series. Reprod Toxicol 2004;19(2):235-8
   PubMed Web of Science ®Google Scholar
• Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27(6):607-13
   PubMed Web of Science ®Google Scholar
• Cole JA, Modell JG, Haight BR, Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16(5):474-84
   PubMed Web of Science ®Google Scholar
• Chun-Fai-Chan B, Koren G, Fayez I, Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005;192(3):932-6
   PubMed Web of Science ®Google Scholar
• Alwan S, Reefhuis J, Botto LD, Maternal use of bupropion and risk for congenital heart defects. Am J Obstet Gynecol 2010;203(1):52, e1-6
   PubMed Web of Science ®Google Scholar
• Djulus J, Koren G, Einarson TR, Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J Clin Psychiatry 2006;67(8):1280-4
   PubMed Web of Science ®Google Scholar
• Moretti ME, Maxson A, Hanna F, Koren G. Evaluating the safety of St. John's Wort in human pregnancy. Reprod Toxicol 2009;28(1):96-9
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson TR, Koren G. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J Obstet Gynaecol Can 2009;31(5):452-6
   PubMedGoogle Scholar
• Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 2010;182(10):1031-7
   PubMed Web of Science ®Google Scholar
• Suri R, Altshuler L, Hellemann G, Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 2007;164(8):1206-13
   PubMed Web of Science ®Google Scholar
• Einarson A, Choi J, Einarson TR, Koren G. Adverse effects of antidepressant use in pregnancy: an evaluation of fetal growth and preterm birth. Depress Anxiety 2010;27(1):35-8
   PubMed Web of Science ®Google Scholar
• Wisner KL, Sit DK, Hanusa BH, Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166(5):557-66
   PubMed Web of Science ®Google Scholar
• Moses-Kolko EL, Bogen D, Perel J, Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293(19):2372-83
   PubMed Web of Science ®Google Scholar
• Levinson-Castiel R, Merlob P, Linder N, Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173-6
   PubMed Web of Science ®Google Scholar
• Tanaka T, Choi J, Einarson A, Koren G, The incidence of poor neonatal adaptation syndrome following exposure to venlafaxine in late pregnancy. Can J Clin Pharmacol 2008;15(3):e420-781
   Google Scholar
• Maschi S, Clavenna A, Campi R, Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 2008;115(2):283-9
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ, Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354(6):579-87
   PubMed Web of Science ®Google Scholar
• Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17(8):801-6
   PubMed Web of Science ®Google Scholar
• Andrade SE, McPhillips H, Loren D, Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18(3):246-52
   PubMed Web of Science ®Google Scholar
• Wilson KL, Zelig CM, Harvey JP, Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28(1):19-24
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE, Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159(11):1889-95
   PubMed Web of Science ®Google Scholar
• Pedersen LH, Henriksen TB, Olsen JF, Exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125(3):e600-8
   PubMed Web of Science ®Google Scholar